A screenshot of a cell phone

Description automatically generated

**Saturday, March 7, 2020**

6:30 am – 7:00 am

**Breakfast with the Vendors**

7:00 am – 9:30 am

**Imaging the Immune System for Personalized Medicine, Immuno-oncology**

***Session Organizer: Michael Graham, MD***

**Scheduled Topics:**

**Utility of Imaging In Immunotherapy**

*Speaker: Michael Graham, MD*

**Treatment Response Criteria in the Era of Immunotherapy**

*Speaker: Hossein Jadvar, MD, PhD*

**New Approaches to Imaging the Immune System***Speaker: Katrin Szardenings, PhD, MBA – Presented Remotely*

4:00 pm– 7:30 pm

**Amino Acid PET for Neuro-oncology: Current Status and Opportunities**

***Session Organizer:*** ***Jonathan McConathy, MD, PhD***

**Scheduled Topics**

**Current techniques for clinical brain tumor imaging***Speaker: Derek Johnson, MD*

**Overview of molecular imaging for neuro-oncology***Speaker: Jonathan McConathy, MD, PhD*

**FDOPA for adult and pediatric neuro-oncology***Speaker: Maria Rosana Ponisio, MD*

**Fluciclovine for neuro-oncology***Speaker: Ephraim Parent, MD, PhD*

**“Theranostic” Approaches for Brain Tumor Therapy**

*Speaker: Christian Behrenbroch, PhD*

**Panel Discussion**

**Sunday, March 8, 2020**

6:30 am – 7:00 am

**Breakfast with the Vendors**

7:00 am – 9:30 am

**ISCHEMIA Trial: Results, Implications, and Challenges**

***Session Organizer: Daniel Berman, MD***

**Scheduled Topics**

**A Deep Dive into the Results***Speaker: Leslee Shaw, PhD*

**Trial Strengths and Limitations**

*Speaker: Panithaya Chareonthaitawee, MD*

**Role of Absolute MBF in the post-ISCHEMIA Trial Era**

*Speaker: Venkatesh Murthy, MD, PhD*

**Implications for Nuclear Cardiology and Coronary CTA**

*Speaker: Daniel Berman, MD*

**Addressing Trial Results Locally**

*Speaker: Robert Hendel, MD*

**Challenges for Nuclear Cardiology: Open Panel Discussion**

4:00 pm – 6:30 pm

**Neuroimaging of Tauopathy and Inflammation**

***Session Organizers: Alan Packard, PhD and Daniel Silverman, MD, PhD, Conference Chair***

In a session that focuses on imaging of tau-based proteinopathy and  inflammatory processes in living human brain, we will cover:  1. How the latest imaging-derived data informs the related neuroscience, and corresponding neurologic work-up (diagnosis,/prognosis, image-guided therapy, etc.), and  2. What is on the near-future horizon with respect to developing commercially viable radiotracers having potential clinical utility, particularly with respect to TBI/CTE and dementia-related disorders.

**Scheduled Topics**

**Tau**

**Neuroimaging of Tau: Progress towards Understanding non-Alzheimer's Neurodegenerative Diseases**

*Speaker: Andrew Stephens, Life Molecular Imaging*

**Neuroimaging of Tau: Progress towards Understanding Its Role in Alzheimer's Spectrum through Normal Aging**

*Speaker: Dan Silverman, University of California, Los Angeles*

**Tau Imaging Radiotracers: Path towards Validation and Commercialization**

*Focused group discussion centered around the FDA's upcoming (23 April 2020) consideration of the first tau PET imaging agent NDA, flortaucipir F18.*

**Neuroinflammation**

**Neuroimaging of Inflammation: Progress towards Understanding Non-neurodenerative and Neurodegenerative-based Cognitive Dysfunction**

*Speaker: Val Lowe, MD*

**Neuroinflammatory Imaging: Path towards Radiotracer Development and Validation**

*Speaker: Katrin Szardenings, PhD, MBA – Presented Remotely*

**Past, Present and Future of Imaging TBI, CTE, MCI, AD and Related Disorders**

**Challenges Imaging TBI and CTE**

*Speaker: Alan Packard*

**Panel Discussion and Global Q&A**

*Panelists: Andrew Stephens, Alan Packard, Dan Silverman, Val Lowe, MD, Katrin Szardenings*

7:00pm – 10:00pm

**Dinner**

**Monday, March 9, 2020**

6:30 am – 7:00 am

**Breakfast with the Vendors**

Monday March 9, 2020

7:00 am – 9:30 am

**Legislative and Regulatory Update**

***Session Chair: Ira Goldman, MA***

2019 witnessed considerable legislative and executive branch activity related to healthcare at both the U.S. Federal and State levels. With Democrats in control of the U.S. House of Representatives there are new battles shaping up over the Affordable Care Act initiated during the Obama Administration.  With a Presidential election already underway, drug pricing was one of the rare areas in which both U.S. political parties agreed that action is necessary, and there was a flurry of legislation related to drug price transparency and negotiations, promotion/facilitation of generic drugs (including changes to the drug patent regime), and “surprise” medical billing.  Although PAMA and MACRA become increasingly distant memories, Appropriate Use Criteria (AUC) and Clinical Decision-Support (CDS) efforts continue to progress. Major gaps in coverage and payment continue to challenge the future of nuclear medicine. This session will provide updates regarding an overview of ongoing legislative and regulatory changes impacting the nuclear medicine sector.

**Scheduled Topics**

**SNMMI Initiatives – President’s Report on Current and Future Directions***Speaker: Alan Packard, PhD*

**Nuclear Medicine Opportunities and Challenges in Washington during a Presidential Election Year**

*Speaker: Sue Bunning, Industry Director, Positron Emission Tomography, Medical Imaging and Technology Alliance*

**FDA Review of Radiopharmaceuticals  
Updates*:*** *Speaker: Lou Marzella, MD, PhD, FDA – Presented Remotely*

**FDA Perspective Clinical Trial Design for Targeted Radionuclide Therapy, Development Considerations**:

*Speaker: Sue-Jane Wang PhD – Presented Remotely*

**FDA Perspective**: **Nostic Clinical Considerations in Theranostic Development:**

*Speaker: Anthony Fotenos MD, PhD – Presented Remotely*

**Reimbursement – Coverage, Payment and Coding**

*Speaker: Denise Merlino*

**Appropriate Use Criteria – What’s New, What’s Revised? - Thyroid and Prostate Cancer, Infection Imaging, etc.**

*Speaker: Kevin Donohoe, MD*

**Panelists:**Alan Packard, Sue Bunning, Lou Marzella, Kevin Donohoe, and Denise Merlino

1:00 pm – 3:00 pm

**Roundtable Discussion: Adding Value to Cardiac PET Using MFR and MBF: A Case-based Approach**

**Moderators: Ernie Garcia, PhD and Val Lowe, MD**

*Speaker: Venkatesh Murthy, MD, PhD*

4:00 pm – 7:30 pm

**Advancing Technology AI and Instrumentation**

**Session Organizers: Ernie Garcia, PhD and Val** **Lowe, MD**

The Artificial Intelligence (AI) portion of this session describes the tools as well as the similarities and differences in the subfields of AI that include decision support systems, machine learning and deep learning. Examples of applications in nuclear medicine are presented. The challenges and opportunities in the future of these important tools will be discussed.

**Scheduled Topics**

**Brief Primer on AI with Imaging Applications***Speaker: Ernie Garcia, PhD*

**Advanced Imaging Applications with Deep Learning and Big Data**

*Speaker: Piotr Slomka, PhD*

**How Long is Long Enough: Long Bore Scanner Physics**

*Speaker: Bernard Bendriem, PhD – Presented Remotely*

**Digital Detectors and Their Transformative Effect on PET Scanner Design and Performance**

*Speaker: Joel Karp, PhD – Presented Remotely*

**Clinical Applications with Long Bore Scanner Technology**

*Speaker: Val J. Lowe, MD*

**Tuesday, March 10, 2020**

6:30 am – 7:00 am

**Breakfast with the Vendors**

7:00 am – 9:30 am

**Emerging Topics in Pediatrics**

***Session Organizers: Barry Shulkin and Alan Packard, PhD***

This session will feature a range of topics related to pediatric nuclear medicine with a focus on what’s new: new imaging agents, new radiotherapeutics, new methodology, and new ways to use established tracers.

**Scheduled Topics:**

**[18F]mFGB and Neuroblastoma**

*Speakers: Speakers: Neeta Pandit-Taskar, MD – Presented Remotely*

***64/67Cu-SARTATE as a Theranostic for the Treatment of Neuroblastoma***

*Speaker: Colin Biggin, PhD*

**[18F]FPEB Imaging in Adolescent Depression and Suicide**

*Speakers: Irina Esterlis PhD – Presented Remotely*

**FDG PET/CT Radiomics in Childhood/Adolescent/Young Adult Osteosarcoma**

*Speakers: Steve Cho, MD*

**131 I- 3F8/ 8H9 for Treatment of CNS Primary and Metastatic Tumors**

*Speakers: Neeta Pandit-Taskar, MD – Presented Remotely*

**FDOPA – NDAs, congenital hyperinsulinism, and pediatric neuro-oncology**

*Speakers: Jonathan McConathy, MD, PhD*

**Panel Discussion and Q&A**

1:00 pm – 3:00 pm

**Roundtable Discussion: Industry – Current Highlights, Unmet Needs, Future Innovations**

Description: Technology and tracers in the realm of multi-modality imaging; timing and perceived clinical need is often the biggest factor in success or failure. With this session we’ll work to “see around the corners” of the role of radionuclide imaging in addressing the biggest healthcare problems.

**Moderators: Edward L. Lyons, RT, CNMT**

4:00 pm – 7:30 pm

**Neuroendocrine Imaging and Targeted Alpha Therapy**

***Session Organizers: Andreas Kjaer, MD, PhD and Roy Brown, BS, MBA***

Description: Following the Novartis acquisition of AAA and Endocyte, pharma has increased their interest in targeted radionuclide therapy. The pipeline is increasing both academically and commercially. Potential speakers from academia and companies as Endocyte, AAA, Bayer, Actinium pharmaceuticals, Nordic Nanovector, 3B pharmaceuticals, clarity pharmaceuticals etc.

**Scheduled Topics:**

**Neuroendocrine cancers using Pb-212 DOTATATE (AlphaMedix™): Dose finding and preliminary efficacy results**

*Speakers: Ebrahim Delpassand, MD*

**64Cu-DOTATATE PET for neuroendocrine tumors: lessons learned from first 1,200 patient scans**

*Speakers: Andreas Kjaer, MD*

**Targeted alpha therapies with Thorium conjugates**

*Speakers: Shaemus Gleason*

**Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First US Prospective Clinical Trial**

*Speakers: Ebrahim Delpassand, MD*

**Wednesday, March 11, 2020**

6:30 am – 7:00 am

**Breakfast with the Vendors**

7:00 am – 9:30 am

**Thyroid / Endocrinology**

***Session Organizer: Michael Wissmeyer, MD***

**Scheduled Topics:**

**Update on approtpriated use criteria (AUC) and controversies in low dose ablation of differentiated thyroid carcinoma (DTC)**

*Speakers: Michael Wissmeyer, MD – Presented Remotely*

**F18-DOPA PET in Medullary Thyroid Cancer**

*Speakers: Claire Tabouret, MD – Presented Remotely*

**F18-Choline PET in Parathyroid Adenomas**

*Speakers: Michael Wissmeyer, MD – Presented Remotely*